A Review and Comparison of Methods for Recreating Individual Patient Data from Published Kaplan-Meier Survival Curves for Economic Evaluations: A Simulation Study

por Wan, Xiaomin, Peng, Liubao, Li, Yuanjian
Publicado 2015

Cost-effectiveness analysis of positron-emission tomography-computed tomography in preoperative staging for nonsmall-cell lung cancer with resected monometastatic disease

por Zeng, Xiaohui, Peng, Liubao, Tan, Chongqing, Wang, Yunhua
Publicado 2019

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in Chi...

por Luo, Xia, Zhou, Zhen, Zeng, Xiaohui, Peng, Liubao, Liu, Qiao
Publicado 2022

The Cost of Treating Advanced Non-Small Cell Lung Cancer: Estimates from the Chinese Experience

por Zeng, Xiaohui, Karnon, Jonathan, Wang, Siying, Wu, Bin, Wan, Xiaomin, Peng, Liubao
Publicado 2012

Comparative efficacy of various CHIs combined with western medicine for non-small cell lung cancer: A bayesian network meta-analysis of randomized controlled trials

por Peng, Ciyan, Chen, Jing, Cui, Wei, Li, Sini, Li, Jianhe, Peng, Liubao
Publicado 2022

A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Canc...

por Wang, Siying, Peng, Liubao, Li, Jianhe, Zeng, Xiaohui, Ouyang, Lihui, Tan, Chongqing, Lu, Qiong
Publicado 2013

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA

por Zeng, Xiaohui, Wan, Xiaomin, Peng, Liubao, Peng, Ye, Ma, Fang, Liu, Qiao, Tan, Chongqing
Publicado 2019

Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis

por Liu, Qiao, Luo, Xia, Peng, Liubao, Yi, Lidan, Wan, Xiaomin, Zeng, Xiaohui, Tan, Chongqing
Publicado 2019

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China

por Liu, Qiao, Luo, Xia, Peng, Liubao, Yi, Lidan, Wan, Xiaomin, Zeng, Xiaohui, Tan, Chongqing
Publicado 2020

Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

por Li, SiNi, Li, JianHe, Peng, LiuBao, Li, YaMin, Wan, XiaoMin
Publicado 2021

Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure

por Li, SiNi, Li, JianHe, Peng, LiuBao, Li, YaMin, Wan, XiaoMin
Publicado 2021

Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China

por Li, SiNi, Li, JianHe, Peng, LiuBao, Li, YaMin, Wan, XiaoMin
Publicado 2021

Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies

por Li, SiNi, Li, JianHe, Peng, LiuBao, Li, YaMin, Wan, XiaoMin
Publicado 2021

Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States

por Li, SiNi, Li, JianHe, Peng, LiuBao, Li, YaMin, Wan, XiaoMin
Publicado 2021

Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China

por Li, Sini, Peng, Liubao, Tan, Chongqing, Zeng, Xiaohui, Wan, Xiaomin, Luo, Xia, Yi, Lidan, Li, Jianhe
Publicado 2020

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer

por Liu, Qiao, Tan, Chongqing, Yi, Lidan, Wan, Xiaomin, Peng, Liubao, Li, Jianhe, Luo, Xia, Zeng, Xiaohui
Publicado 2021

PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China

por Liu, Qiao, Luo, Xia, Zhou, Zhen, Peng, Liubao, Yi, Lidan, Wan, Xiaomin, Tan, Chongqing, Zeng, Xiaohui
Publicado 2021

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis

por Liu, Qiao, Zhou, Zhen, Luo, Xia, Yi, Lidan, Peng, Liubao, Wan, Xiaomin, Tan, Chongqing, Zeng, Xiaohui
Publicado 2021

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

por Liu, Qiao, Zhou, Zhen, Luo, Xia, Yi, Lidan, Peng, Liubao, Wan, Xiaomin, Tan, Chongqing, Zeng, Xiaohui
Publicado 2022

Economic Evaluation of First-Line Adjuvant Chemotherapies for Resectable Gastric Cancer Patients in China

por Tan, Chongqing, Peng, Liubao, Zeng, Xiaohui, Li, Jianhe, Wan, Xiaomin, Chen, Gannong, Yi, Lidan, Luo, Xia, Zhao, Ziying
Publicado 2013